medigraphic.com
SPANISH

Revista Clínica de la Escuela de Medicina de la Universidad de Costa Rica

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 2

<< Back Next >>

Rev Clin Esc Med 2019; 9 (2)

Disfunción ejecutiva en la Enfermedad de Huntington en fase preclínica versus fase clínica

Radulovich MM, González SM, Monge OJM
Full text How to cite this article

Language: Spanish
References: 8
Page: 77-83
PDF size: 497.30 Kb.


Key words:

Early stage, executive function, huntington´s disease, pre clinical.

ABSTRACT

Huntington’s disease has been studied largely by its motor symptomatology, but cognitive and psychiatric affections appear to years before the motor debut. Neuropsychiatric symptoms represent an important load for patients and their families for the loss of independence of those who suffer them. The objective of this work is to carry out a research of the specific cognitive symptoms that differ them to carry out only the basic daily activities, the references to the executive system. By identifying the main affections of patients from early stages, a more efficient therapeutic approach can be designed. The review was carried out with studies of the last six years, that were empirical studies and that included patients with the grouped disease according to its evolution. Within the studies used, different methods of evaluation of the executive system applied. Both psychiatric and cognitive symptoms are valued within the executive function and how they evolve in the course of disease. The results point out to an important executive dysfunction from initial stages of the disease, in particular an increased risk of apathy since very early in the situation.


REFERENCES

  1. Testa C M Jankovic J. Huntington disease: A quarter century of progress since the gene discovery. Journal of the Neurological Sciences, 2018, 396; 52-68.

  2. Mörkl S Müller N J Blesl C Wilkinson L Tmava A Wurm W Painold A. Problem solving, impulse control and planning in patients with early- and latestage Huntington’s disease. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266(7); 663-671.

  3. Walker F O. Huntington’s disease. The Lancet, 2007, 369(9557); 218-228.

  4. Domínguez D Poudel G Stout J C Gray M Chua P Borowsky B Georgiou-Karistianis N. Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington’s disease: 30 months IMAGE-HD data. CORTEX. 2017; 92: 139-149.

  5. Martínez-Horta S Perez-Perez J van Duijn E Fernandez-Bobadilla R Carceller M Pagonabarraga J Kulisevsky J Neuropsychiatric symptoms are very common in premanifest and early stage Huntington’s Disease. Parkinsonism & Related Disorders, 2016, 25; 58-64.

  6. Unschuld P G Liu X Shanahan M Margolis L Bassett S S Brandt J Ross C A. Prefrontal executive function associated coupling relates to Hungtinton’s disease stage. CORTEX, 2013, 49(10); 2661-2673.

  7. Maurage P Heeren A Lahaye M Jeanjean A Guettat L Verellen-Dumoulin C Constant E. Attentional impairments in Huntington’s disease: A specific deficit for the executive conflict. Neuropsychology, 2017, 31(4); 424-436.

  8. Langbehn D R. Criteria for success in safety and tolerability trials. The Lancet Neurology, 2015; 14(1), 24-25.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Clin Esc Med. 2019;9